TOP TEN perturbations for 1553313_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1553313_s_at
Selected probe(set): 213164_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1553313_s_at (213164_at) across 6672 perturbations tested by GENEVESTIGATOR:
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):3.5600348Number of Samples:6 / 12
| Experimental | IL-4; GM-CSF study 1 (late) |
| Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
| Control | untreated monocyte sample |
| Freshly isolated human monocytes from healthy donors. |
stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) / stem cell differentiation study 47 (0d)
Relative Expression (log2-ratio):3.4237118Number of Samples:3 / 6
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; IBMX; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml), transforming growth factor beta (TGFb, 5 ng/ml) and 3-isobutyl-1-methylxanthine (IBMX, 250 μM). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb, 250 μM IBMX), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (0d) |
| Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
IL-4; GM-CSF study 1 (early) / untreated monocyte sample
Relative Expression (log2-ratio):3.3603878Number of Samples:6 / 12
| Experimental | IL-4; GM-CSF study 1 (early) |
| Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours. | |
| Control | untreated monocyte sample |
| Freshly isolated human monocytes from healthy donors. |
Langerhans cell histiocytosis study 2 (multifocal) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):3.2717342Number of Samples:2 / 10
| Experimental | Langerhans cell histiocytosis study 2 (multifocal) |
| Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal (bone, skin lesions) disease. | |
| Control | normal epidermal Langerhans cell sample |
| Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (BMP-2; TGFb; 1d)
Relative Expression (log2-ratio):3.2355947Number of Samples:3 / 3
| Experimental | stem cell differentiation study 47 (BMP-2; TGFb; 7d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). | |
| Control | stem cell differentiation study 47 (BMP-2; TGFb; 1d) |
| Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 24 hours in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 24 hours in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458). |
influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):3.2286444Number of Samples:3 / 3
| Experimental | influenza virus study 11 (A/H5N3) |
| Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Relative Expression (log2-ratio):3.1990547Number of Samples:2 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported. |
TGF-ß3 study 1 (intermediate) / untreated mesenchymal stem cell sample
Relative Expression (log2-ratio):3.1490583Number of Samples:6 / 5
| Experimental | TGF-ß3 study 1 (intermediate) |
| Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were stimulated with 10ng/ml of recombinant TGF-ß3 for 3 days or 7 days. (Warning: Experiment with gender bias). | |
| Control | untreated mesenchymal stem cell sample |
| Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were not treated. (Warning: Experiment with gender bias). |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.9812918Number of Samples:3 / 3
| Experimental | influenza virus study 9 (A/pH1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
| Control | influenza virus study 4 (A/H1N1) |
| Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)
Relative Expression (log2-ratio):2.9487877Number of Samples:3 / 11
| Experimental | HCC study 20 (CDX; Hep-G2; ectopic) |
| Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. | |
| Control | HCC study 20 (PDX; ectopic) |
| Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks. |